Gastro protective and H(+), K(+)-ATPase/H. pylori inhibitory properties of pectic polysaccharides from potato.

Polysaccharide is one among the important classes of biological polymers that is reported to exhibit disease preventive properties. The present study describes the isolation of galactans and confirmation of the same by sugar analysis and determination of anti-ulcer effect of Potato Galactan Polysaccharide (PGP). Data indicated that PGP possessed sugar composition of rhamnose (2%), arabinose (3%), mannose (3%), galactose (94%) and uronic acid (17%) confirming that PGP thus isolated is a galactan. PGP exhibited potent H(+), K(+)-ATPase inhibitory activity (IC50 420 µg/mL) in vitro as opposed to lansoprazole, a known antiulcer drug with IC50 19.3 µg/mL. The antiulcer potency of PGP was evaluated in ethanol stress induced gastric ulcer model in vivo. About 84% reduction in ulcer index; enhanced mucosal recovery, normalization of H(+), K(+)-ATPase, antioxidant and antioxidant enzymes substantiated the antiulcer potentials of PGP. Mucosal recovery could be attributed to cytoprotective and DNA protective ability of PGP that can help in mucosal layer regeneration. Further, PGP was also effective in inhibiting Helicobacter pylori as per growth inhibition assay followed by scanning electron microscopic studies suggesting that PGP is effective in curbing the growth of H. pylori, which is responsible for ∼70% of gastric ulcer/cancer incidences.

Role of epidermal growth factor receptor transactivation in PPAR gamma-dependent suppression of Helicobacter pylori interference with gastric mucin synthesis.

Peroxisome-proliferator-activated receptor gamma (PPARgamma) is recognized for its role in regulation of genes associated with inflammation, and its activation of phosphatidylinositol 3-kinase (PI3K) has emerged recently as an important regulator of mucosal responses to bacterial infection. In this study, we report that PPARgamma activation leading to the impedance of Helicobacter pylori lipopolysaccharide (LPS) inhibitory effect on salivary mucin synthesis requires epidermal growth factor receptor (EGFR) participation. Using gastric mucosal cells in culture, we show that activation of PPARgamma with a specific agonist, ciglitazone, prevents the LPS-induced reduction in mucin synthesis, and the effect is reflected in a marked decrease in apoptosis, caspase-3 activity and NO generation. The impedance by ciglitazone of the LPS-induced reduction in mucin synthesis was blunted (up to 65.8%) in a concentration-dependent fashion by a specific inhibitor of EGFR kinase, PD153035, as well as the PPARgamma antagonist BADGE, and wortmannin, an inhibitor of PI3K. Moreover, the inhibitory effect of ciglitazone on the LPS-induced reduction in mucin synthesis and upregulation in apoptosis, caspase-3 activity and NO generation was countered by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR transactivation. These findings indicate that PPARgamma activation leading to the suppression of H. pylori LPS inhibition of gastric mucin synthesis involves Src kinase-dependent EGFR transactivation.

The effects of reductive dissociation of gastric mucin isolated in the presence of proteinase inhibitors.

Mucin was purified by the gel filtration method on columns with high porous molecular sives in buffers with SDS and proteinase inhibitors. The addition of proteinase inhibitors distinctly inhibited proteolytic activity. It was found that the obtained mucin, after disulphide-bound reduction, is dissociated to mucin subunits and N-glycosylated glycoprotein of molecular weight about 75 kDa. This protein has carbohydrate and amino acid composition different from high molecular fraction. The 75 kDa protein is strongly associated with high molecular mass mucin subunits and can be separated either during electrophoresis or fractionation in buffers with 2-mercaptoethanol.